Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant–abemaciclib. Primary end points were investigator-assessed progression-free ...

Herein we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. Abemaciclib+fulvestrant ...

So, ribociclib is still in the dose-finding area. Abemaciclib has completed phase II. Palbociclib is ready to go in dose expansion at full dose of 125 mg. Everolimus, the RP2D [recommended phase ...

The combination of imlunestrant and abemaciclib further enhanced PFS to 9.4 months, regardless of ESR1 mutation status. Consistent benefits were observed across subgroups, including those with ...

This page includes links to articles highlighting the top breast cancer research published on Cancer Therapy Advisor in 2024.

“The main purpose of this EMBER-3 trial was to evaluate the role of imlunestrant, a brain-penetrant oral SERD, as monotherapy or in combination with the CDK4/6 inhibitor, abemaciclib, in ...

"The main purpose of this EMBER-3 trial was to evaluate the role of imlunestrant, a brain-penetrant oral SERD, as monotherapy or in combination with the CDK4/6 inhibitor, abemaciclib, in patients ...

This progression-free survival benefit with imlunestrant did not extend to the overall population, but a combination of imlunestrant plus abemaciclib did lead to a significant improvement in ...

Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safety profile for the combination of abemaciclib 150 mg twice daily (BID) with the recommended Phase 3 ...

Arvinas and Pfizer have shared preliminary outcomes from the Phase Ib segment of the TACTIVE-U sub-trial of vepdegestrant plus abemaciclib for treating individuals with locally advanced or ...